DLL4在乳腺癌中的表达及临床意义  

The Clinical Significance of Expression of DLL4 and in Breast Carcinoma

作　　者：郎志强[1] 吴艳秋[2] 姜蕾[1] 曲桂梅[1] 潘旭波[1] 王威[1] 

机构地区：[1]山东省烟台毓璜顶医院病理科,264000 [2]山东省烟台毓璜顶医院儿科,264000

出　　处：《中华全科医学》2012年第9期1374-1375,1490,共3页Chinese Journal of General Practice

基　　金：山东省烟台市科技发展计划资助项目(2008142-15)

摘　　要：目的研究Delta样配体4(Delta-like Ligand4,DLL4)在乳腺癌中的表达及临床意义。方法通过免疫组织化学染色及组织芯片方法检测122例乳腺浸润性导管癌和28例导管原位癌中DLL4的表达,结合临床病理学资料进行统计分析。结果 DLL4在乳腺导管原位癌、浸润性导管癌Ⅰ级、浸润性导管癌Ⅱ级、浸润性导管癌Ⅲ级中的表达率分别为21.4%、48.5%、75%、91.8%,其表达随分级的增高而增高,各组相比差异有统计学意义(P均<0.05),而且DLL4的表达与肿瘤大小、临床分期及淋巴结转移状态呈正相关(P均<0.05),与患者年龄、雌激素受体、孕激素受体及HER2表达情况无相关性(P均>0.05)。结论 DLL4的作用在乳腺癌演进晚期较早期强,可能与乳腺癌的发展及预后相关,可作为预测乳腺癌预后的重要参考指标及乳腺癌靶向治疗的新靶点。Objective To study the expression of DLL4 （ Delta-like ligand 4） in breast carcinoma and its clinical significance. Methods Tissue chip and immunohistoehemical staining were used to exalnine the expression of DLIA in 122 cases of invasive breast carcinoma and 28 cases of duetal carcinoma in situ（DCIS）. The results and clinical-pathological data were analyzed statistically. Results The positive rate of DLL4 in DCIS,invasive breast carcinoma grade I , grade II and grade III was 21.4% , 48.5 %, 75 % and 91.8 % respectively, and the expression of DLL4 was increased accompanied with the histological grade and related with the tumor size ,TNM stage,lymph node state （P 〈 0.05 ）, but was irrelevant to age, ER, PR and HER2 expression.（ P 〉 0.05 ）. Conclusion DLL4 might play a more important role in high grade breast carcinomas than in low grade ones and be related with the development and prognosis of human breast carcinoma. It may be an important marker to predict prognosis of breast carcinoma and could be a new target for therapy.

关 键 词：DLIA 乳腺肿瘤 组织芯片 免疫组织化学 

分 类 号：R737.9[医药卫生—肿瘤] R730.27[医药卫生—临床医学]